An experimental drug regimen under development by AbbVie could change the way hepatitis C is treated, according to a special designation it received from the Food and Drug Administration.
According to research published in the New England Journal of Medicine, not all respiratory ailments that generate influenza-like symptoms can be attributed to the flu.
A drug maker and medical research institute will work together to identify new treatments for bacterial and viral infections.
A phrase like “silent killer” sounds creepy enough on its own, but it’s an often-used one for a virus that, according to the Centers for Disease Control and Prevention, infects 1.3% to 1.9% of people in the United States.
Since the beginning of the HIV/AIDS epidemic in the early 1980s, one of the greatest advances has been antiviral drugs that have helped extend the lives of patients with viral infections.
Drug makers Valeant Pharmaceuticals International and Kadmon Pharmaceuticals will collaborate to develop antiviral drugs for...
The market for hepatitis C drugs could get a boost if a clinical trial program...